ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Dihydromyricetin ameliorates vascular calcification in chronic kidney disease by targeting AKT signaling

Feng, Liyun; Que, Dongdong; Li, Zehua; Zhong, Xinglong; Yan, Jing; Wei, Jintao; Zhang, Xiuli; Yang, Pingzhen; Ou, Caiwen*; Chen, Minsheng*南方医科大学
Clinical Science2021-11DOI: 10.1042/CS20210259
6被引11阅读
引用收藏
分享

摘要

Vascular calcification is highly prevalent in chronic kidney disease (CKD), and is characterized by transdifferentiation from contractile vascular smooth muscle cells (VSMCs) into an osteogenic phenotype. However, no effective and therapeutic option to prevent vascular calcification is yet available. Dihydromyricetin (DMY), a bioactive flavonoid isolated from Ampelopsis grossedentata, has been found to inhibit VSMCs proliferation and the injury-induced neointimal formation. However, whether DMY has an effect on osteogenic differentiation of VSMCs and vascular calcification is still unclear. In the present study, we sought to investigate the effect of DMY on vascular calcification in CKD and the underlying mechanism. DMY treatment significantly attenuated calcium/phosphate-induced calcification of rat and human VSMCs in a dose-dependent manner, as shown by Alizarin Red S staining and calcium content assay, associated with down-regulation of osteogenic markers including type I collagen (COL I), Runt-related transcription factor 2 (RUNX2), bone morphogenetic protein 2 (BMP2) and osteocalcin (OCN). These results were further confirmed in aortic rings ex vivo. Moreover, DMY ameliorated vascular calcification in rats with CKD. Additionally, we found that AKT signaling was activated during vascular calcification, whereas significantly inhibited by DMY administration. DMY treatment significantly reversed AKT activator-induced vascular calcification. Furthermore, inhibition of AKT signaling efficiently attenuated calcification, which was similar to that after treatment with DMY alone, and DMY had a better inhibitory effect on calcification as compared with AKT inhibitor. The present study demonstrated that DMY has a potent inhibitory role in vascular calcification partially by inhibiting AKT activation, suggesting that DMY may act as a promising therapeutic candidate for patients suffering from vascular calcification.

学科与关键词

关键词
ANTIOXIDANT ACTIVITIESOXIDATIVE STRESSDOWN-REGULATIONUP-REGULATIONHEPG2 CELLSIN-VITROACTIVATIONMECHANISMSAPOPTOSISCALCIUM
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Clinical Science
发表日期
2021-11
卷期
第 135 卷, 第 21 期
页码
2483-2502
DOI
10.1042/CS20210259
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81971765, 31771060, 31771099, 81871504]

作者

  • F

    Feng, Liyun (第一作者)

    southern med univ

  • Q

    Que, Dongdong

    southern med univ

查看全部 10 位作者收起作者
  • L

    Li, Zehua

    southern med univ

  • Z

    Zhong, Xinglong

    southern med univ

  • Y

    Yan, Jing

    southern med univ

  • W

    Wei, Jintao

    southern med univ

  • Z

    Zhang, Xiuli

    southern med univ

  • Y

    Yang, Pingzhen

    southern med univ

  • O

    Ou, Caiwen (通讯)

    southern med univ

  • C

    Chen, Minsheng (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417